感染

订阅

MedSci主页 / 所有栏目 / 感染

J Urban Health：艾滋病毒传播与种族/民族/地域差异之间的联系

2017-09-29 佚名 Medical Xpress

艾滋病传播地理因素
关注

人们生活，工作和健康有很好的记录，以及旨在改善健康的邻里级结构性干预措施有很大的价值。但是，导致艾滋病毒传播和疾病负担差距的基于地方特征的了解甚少，这可能导致减少艾滋病毒的干预措施和计划编制效率低下。

人们生活，工作和健康有很好的记录，以及旨在改善健康的邻里级结构性干预措施有很大的价值。但是，导致艾滋病毒传播和疾病负担差距的基于地方特征的了解甚少，这可能导致减少艾滋病毒的干预措施和计划编制效率低下。

宾夕法尼亚大学护理学院（Penn Nursing）的一项新研究正在帮助我们更好地了解推动艾滋病毒/艾滋病不同的社会和结构因素，以及如何更有效地对抗艾滋病毒/艾滋病流行病。

最近发表在“城市卫生杂志”上的22个月的试点研究探讨了城市艾滋病毒感染者，艾滋病毒传播模式中的种族/民族和地域差异。数据表明，某些地理位置似乎具有不同的传播模式，性别和种族/民族的差异微乎其微。

研究助理教授Bridgette M. Brawner博士解释说：“我们对导致艾滋病毒传播和疾病负担不均衡的基础地理因素也不甚了解。”“一尺度”不适合个人层面的干预，在受影响较大的社区也是如此，特别是当风险状况因邻里特征和人口特征而异时。这一研究产生的数据支持了一个非常必要的结论，即艾滋病毒/艾滋病流行病导致社会和社会凝聚力有限。这可能是社会凝聚力不足，健康相关资源不足，社会贫困等不利因素的作用，这些调查结果还将更好地指导邻近层面的结构性干预措施，以解决负担过重的社区艾滋病毒/艾滋病问题”。

原始出处：Bridgette M. Brawner, Barbara Guthrie, Robin Stevens, et al. Place Still Matters: Racial/Ethnic and Geographic Disparities in HIV Transmission and Disease Burden.Journal of Urban Health (2017)

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=253025, encodeId=16732530259b, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 15 07:25:20 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249652, encodeId=d490249652f3, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Oct 02 10:27:03 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621666, encodeId=1e5c16216667d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Oct 01 13:17:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861157, encodeId=0c64186115eae, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 07:17:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248985, encodeId=6710248985bc, content=好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Sep 30 06:18:35 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248912, encodeId=048c24891220, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Sep 29 22:45:02 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-15 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=253025, encodeId=16732530259b, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 15 07:25:20 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249652, encodeId=d490249652f3, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Oct 02 10:27:03 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621666, encodeId=1e5c16216667d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Oct 01 13:17:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861157, encodeId=0c64186115eae, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 07:17:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248985, encodeId=6710248985bc, content=好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Sep 30 06:18:35 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248912, encodeId=048c24891220, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Sep 29 22:45:02 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-02 往日如昨

    继续学习中谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=253025, encodeId=16732530259b, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 15 07:25:20 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249652, encodeId=d490249652f3, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Oct 02 10:27:03 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621666, encodeId=1e5c16216667d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Oct 01 13:17:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861157, encodeId=0c64186115eae, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 07:17:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248985, encodeId=6710248985bc, content=好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Sep 30 06:18:35 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248912, encodeId=048c24891220, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Sep 29 22:45:02 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-01 yyanpro@28cn.c

    #Health#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=253025, encodeId=16732530259b, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 15 07:25:20 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249652, encodeId=d490249652f3, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Oct 02 10:27:03 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621666, encodeId=1e5c16216667d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Oct 01 13:17:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861157, encodeId=0c64186115eae, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 07:17:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248985, encodeId=6710248985bc, content=好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Sep 30 06:18:35 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248912, encodeId=048c24891220, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Sep 29 22:45:02 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-07-19 shizhenshan

    #ALT#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=253025, encodeId=16732530259b, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 15 07:25:20 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249652, encodeId=d490249652f3, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Oct 02 10:27:03 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621666, encodeId=1e5c16216667d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Oct 01 13:17:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861157, encodeId=0c64186115eae, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 07:17:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248985, encodeId=6710248985bc, content=好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Sep 30 06:18:35 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248912, encodeId=048c24891220, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Sep 29 22:45:02 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-30 忠诚向上

    好好努力学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=253025, encodeId=16732530259b, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 15 07:25:20 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249652, encodeId=d490249652f3, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Mon Oct 02 10:27:03 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621666, encodeId=1e5c16216667d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sun Oct 01 13:17:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861157, encodeId=0c64186115eae, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Thu Jul 19 07:17:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248985, encodeId=6710248985bc, content=好好努力学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Sep 30 06:18:35 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248912, encodeId=048c24891220, content=不错的文章值得推荐一下了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Sep 29 22:45:02 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 131****2916

    不错的文章值得推荐一下了

    0

相关资讯

BMC Bioinformatics：耐药性的计算建模，以帮助艾滋病患者选择正确疗法

临床上记录的艾滋病毒突变的生物信息学检查可以帮助指导抗逆转录病毒疗法的选择。

J INFECT DIS实现国家艾滋病毒/艾滋病战略将挽救患者生命

由马萨诸塞州总医院（MGH）调查人员组成的分析显示，到2020年实现国家艾滋病战略（NHAS）的治疗目标，不仅可以防止数十万新的感染和死亡，而且还将显示出卓越的价值。他们在“传染病杂志”上发表的研究发现，符合NHAS目标--90％的艾滋病毒感染者知道他们的诊断，其中80％通过抗逆转录病毒药物治疗（ART）实现病毒学抑制。

PNAS：研究确定艾滋病毒发展和传播的“根源”，全新治疗方案即将问世

【感染的HIV病毒霸占了细胞内通路，完成复制】美国西北医学院的一项研究发现，人类免疫缺陷病毒(HIV)使用名为透明甲酸精(DRFs)的蛋白质劫持健康细胞的细胞骨架，这一发现加深了了解艾滋病毒感染，以及开发潜在治疗目标的新方法。在报告中，研究人员指出细胞骨架使细胞的结构完整，帮助促进胞内运输，细胞骨架有两个非常重要的组成部分，肌动蛋白和微管。而DRFs霸占了细胞骨架协调攻击的功能。病毒已经进化了，从

上海药店开售艾滋病唾液快检试剂，10-15分钟出结果

9月29日，上海市HIV快检试剂药店销售项目在上海静安区雷允上药城召开，这标志着HIV（艾滋病病毒）唾液快检试剂药店销售的试点工作在本市正式启动。

Conversation：感染艾滋病毒的同性恋和双性恋肛门癌流行及其预防方法

2014年，美国近620,000名同性恋双性恋男子感染艾滋病毒，其中10万人甚至不知道感染艾滋病毒。这些男性患肛门癌的可能性要比艾滋病毒阴性男性高出100倍。然而，在任何人群中，都没有针对肛门癌预防的国家筛查指南。

关于艾滋病：你需要了解的九个真相！

这里有九个你需要了解的艾滋病的真相。